6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Multi-statute (no §101) | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 58.1% | +39.9% |
| DUFFY, BRADLEY | 1 | 54.6% | +45.5% |
| ALLEN, MARIANNE P | 1 | 60.2% | +18.2% |
| TAKENAKA, RISA | 1 | 28.6% | +100.0% |
| BUTTICE, AUDREY L | 1 | 47.1% | +26.0% |
| BALLARD, KIMBERLY | 1 | 53.9% | +48.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | DUFFY, BRADLEY | 49d overdue |
| 17783505 | CD122 WITH ALTERED ICD STAT SIGNALING | BALLARD, KIMBERLY | 14d |
| 17758830 | IL2 Orthologs and Methods of Use | BUTTICE, AUDREY L | 15d |
| 17916739 | HUMAN IMMUNE CELLS GENOMICALLY MODIFIED TO EXPRESS ORTHOGONAL RECEPTORS | TAKENAKA, RISA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | DUFFY, BRADLEY | 49d overdue |
| 18040260 | CD45 BINDING MOLECULES AND METHODS OF USE | ALLEN, MARIANNE P | 9d overdue |
| 17783505 | CD122 WITH ALTERED ICD STAT SIGNALING | BALLARD, KIMBERLY | 14d |
| 17758830 | IL2 Orthologs and Methods of Use | BUTTICE, AUDREY L | 15d |
| 18576329 | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY OF NEOPLASTIC DISEASE | REDDIG, PETER J | — |
| 17916739 | HUMAN IMMUNE CELLS GENOMICALLY MODIFIED TO EXPRESS ORTHOGONAL RECEPTORS | TAKENAKA, RISA | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1643 | 1 |
| 1632 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576329 | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY OF NEOPLASTIC DISEASE | REDDIG, PETER J | — | §103 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | DUFFY, BRADLEY | 1643 | §102§103§112Other | Non-Final OA | 49d overdue | Pending | Jul 07, 2023 |
| 18040260 | CD45 BINDING MOLECULES AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 9d overdue | Pending | Feb 01, 2023 |
| 17916739 | HUMAN IMMUNE CELLS GENOMICALLY MODIFIED TO EXPRESS ORTHOGONAL RECEPTORS | TAKENAKA, RISA | 1632 | §103§112 | Final Rejection | — | Pending | Oct 03, 2022 |
| 17758830 | IL2 Orthologs and Methods of Use | BUTTICE, AUDREY L | 1647 | §103§112Other | Non-Final OA | 15d | Pending | Jul 14, 2022 |
| 17783505 | CD122 WITH ALTERED ICD STAT SIGNALING | BALLARD, KIMBERLY | 1675 | §102§103Other | Non-Final OA | 14d | Pending | Jun 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial